Ask a Question
    Banner

    Answers in CME Program 2026

     

    Secondary Stroke Prevention Today and Tomorrow: Where Evolving Antithrombitic Strategies May Fit Into Hospitalist Care

    Support: This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

    Available at: https://answersincme.com/HYZ821

     

    Activity Description and Educational Objectives

    In this activity, experts in preventive cardiology and hospital medicine discuss secondary stroke prevention strategies for hospitalists and internists.

    Upon completion of this activity, participants should be better able to:

    • Evaluate guideline-recommended secondary stroke prevention strategies after ischemic stroke or TIA 
    • Describe the clinical rationale for FXIa inhibitors 
    • Discuss the clinical significance of the latest efficacy and safety data for FXIa inhibitors in secondary stroke prevention 
    • Apply best practices for transitioning patients from inpatient to outpatient secondary stroke prevention care

     

    Target Audience

    This activity has been designed to meet the educational needs of hospitalists/internists, APPs and other clinicians in the US.

     

    Faculty Disclosure Statement / Conflict of Interest Policy

    Answers in CME adheres to the standards and guidelines of the Accreditation Council for Continuing Medical Education (ACCME), including the Standards for Integrity and Independence in Accredited CE, and all other professional organizations, as applicable. Any individuals in a position to control the content of a CME/CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies within the past 24 months.

    All relevant financial relationships have been mitigated prior to the commencement of the activity.

    The faculty have the following relevant financial relationships with ineligible companies:

    Faculty

    Keith C. Ferdinand, MD 
    Professor of Medicine 
    Gerald S. Berenson Endowed Chair in Preventative Cardiology 
    Tulane University School of Medicine 
    New Orleans, Louisiana

    Keith C. Ferdinand, MD, has relevant financial relationship(s) with ineligible companies 
    in the form of: 
    Consultant and/or Advisor for Boehringer Ingelheim; Janssen Pharmaceuticals; Lilly; Medtronic; and Novartis.

     

    Henry J. Michtalik, MD, MPH, MHS 
    Assistant Professor 
    Johns Hopkins University School of Medicine 
    Armstrong Institute for Patient Safety and Quality 
    Johns Hopkins Bloomberg School of Public Health 
    Baltimore, Maryland

    Henry J. Michtalik, MD, MPH, MHS, has relevant financial relationship(s) with ineligible 
    companies in the form of: 
    Grant/Research Support from Pfizer, Inc.

    Planners, independent reviewers, and staff of Answers in CME have no relevant financial relationships with ineligible companies to disclose.

     

    Disclosure of Unlabeled Use

    The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use in certain jurisdictions. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

    No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our materials. No responsibility is taken for errors or omissions in our materials.

    Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

     

    Accreditation

    Answers in CME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Answers in CME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The Accreditation Council for Continuing Medical Education (ACCME) is recognized by the World Federation for Medical Education (WFME) as meeting globally accepted standards for CPD accreditation, ensuring that the education they accredit supports high-quality lifelong learning for healthcare professionals.

     

    MOC Statement 

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

     

    Requirements for Successful Completion

    To receive credit, participants must complete the activity, the post-test, and the evaluation form prior to the expiration date noted below. There are no pre-requisites and there is no fee to participate in this activity or to receive credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form. Consult your professional licensing board for information about your eligibility to claim credit for participation in this educational activity. A minimum performance level of 80% is needed.

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 80% or higher is needed to obtain MOC/CC credit.

    Media: Enduring Material 
    Release and Expiration Dates: April 21, 2026 - April 20, 2027 
    Time to Complete: 30 minutes

     

    Disclaimer

    The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Answers in CME or any of its supporters.

     

    This activity is supported by an educational grant from Bayer AG. Bayer AG has had no involvement in the selection of speakers, the development of this activity, the agenda or the materials.

    This presentation may contain information regarding investigational products for which market authorization has not been obtained from Health Canada.

    MA-M_ASUN-CA-0019-1